Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Adefovir Dipivoxil Tablets 10 mg (SigmaPharm Laboratories, USA)
Section 19A approved medicine
Adefovir Dipivoxil Tablets 10 mg (SigmaPharm Laboratories, USA)
Section 19A approval holder
Arrotex Pharmaceuticlas Pty Ltd ABN 30 605 552 234
Phone
1800 276 839
Approved until
Status
Current
Medicines in short supply/unavailable
APO-Adefovir adefovir dipivoxil 10mg tablet bottle - ARTG 212048
Indication(s)
- Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- For adult patients, this indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg-/HBVDNA+ chronic hepatitis B with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.
- For adolescent patients (12 to < 18 years of age), the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus with compensated liver function.
Images
